Axial Spondyloarthritis
Conditions
Interventions
Trade Name: HUMIRA
Product Name: ADALIMUMAB
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: ADALIMUMAB
CAS Number: 331731-18-1
Current Sponsor code: n/a
Concentr
Sponsors
CLINICAL PHARMACOLOGY SPANISH SOCIETY
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 190 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To demonstrate that patients with espondilartritis in remission under antiTNF therapy can maintain the remission with a maintenance dose inferior to the currently recommended dose schedule;Secondary Objective: ;Primary end point(s): FALTA TEXTO INGLES;Timepoint(s) of evaluation of this end point: 1 YEAR | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): FALTA TEXTO INGLES;Timepoint(s) of evaluation of this end point: 1 and 2 years | — |
Countries
Spain
Contacts
Public ContactCRISTINA AVENDAÑO-SOLÁ
CLINICAL PHARMACOLOGY DEPARTMENT- UNIVERSITARY HOSPITAL "PUERTA DE HIERRO"
Outcome results
None listed